Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

AstraZeneca to acquire cell therapy specialist Gracell in deal worth up to $1.2bn

The transaction includes a clinical-stage candidate being evaluated as a treatment for multiple myeloma

- PMLiVE

World Health Organization adds second malaria vaccine to prequalification list

The addition is expected to result in sufficient malaria vaccine supply for children

- PMLiVE

T is for trouble

Evolution trumps transformation

- PMLiVE

GSK gains rights to Hansoh’s ADC candidate in deal worth more than $1.7bn

HS-20093 is being developed for a range of solid tumour types, including lung cancer

- PMLiVE

Nanoparticle-delivered RNA could offer potential therapy for neuroinflammation

The study demonstrated a new way to deliver RNA to the brain's immune cells

- PMLiVE

AstraZeneca/Merck’s Lynparza recommended by NICE for advanced prostate cancer

The combination therapy has been recommended for patients regardless of biomarker status

- PMLiVE

EMA and HMAs publish workplan to guide use of AI in medicines regulation

The document aims to maximise the benefits and mitigate the risks of AI in medicine

- PMLiVE

Reaching the full potential of gene therapy through increased genetic testing

How early diagnosis and advances in gene-focused treatments could transform the lives of patients with rare cardiovascular disease

KVA Christmas Present Appeal 2023

KVA drive Christmas present appeal for children’s hospital

Every year, KVA organise a Christmas present appeal for Stoke Mandeville Hospital, Buckinghamshire and this year their team felt especially generous with a huge collection of Christmas presents.

KVA

- PMLiVE

Gilead gains rights to Compugen’s immunotherapy programme in deal worth $848m

The high affinity antibody blocks the interaction between IL-18 binding protein and IL-18

- PMLiVE

ICR study increases understanding of advanced breast cancer complication

Breast cancer leptomeningeal metastasis affects one in 20 people with metastatic cases

EU flag

EC approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links